Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Humana, private equity firms buy Kindred Healthcare for $810 million

U.S. health insurer Humana Inc. and two private equity firms agreed to buy home healthcare and long-term care operator Kindred Healthcare Inc. for about $810 million, the latest expansion by an American health insurer into patient care.

Read More »

Novo Nordisk wins EU panel’s backing for key diabetes drug

Novo Nordisk came closer to winning European approval for the company’s diabetes drug Ozempic, the Danish drugmaker’s largest growth prospect, when a European Medicines Agency experts’ panel issued a positive recommendation.

Read More »

Germany’s Merck in fresh bid to enter U.S. MS pill market

Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated the German company’s ambitions almost seven years ago.

Read More »

Revance will wait to seek backing for Botox-rival

Revance Therapeutics Inc. will wait to seek partnerships with bigger drugmakers until the company is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.

Read More »

Smart Hospitals to Invest over $11 billion in Cloud Computing and Data Analytics, Says Frost & Sullivan

By 2025, 10 percent of hospitals across the globe will become or will have started implementations to become smart hospitals.

Read More »

Sage’s depression drug succeeds in study

Sage Therapeutics Inc.’s drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

Read More »

Roche drug cocktail doubles chance of holding lung cancer at bay

Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labelled unprecedented.

Read More »

UnitedHealth to buy DaVita primary care unit

The largest U.S. health insurer UnitedHealth Group Inc will buy DaVita Inc’s primary and urgent care services for $4.9 billion in its second acquisition this year.

Read More »

FDA approves Novo Nordisk’s Ozempic

The U.S. FDA approved Novo Nordisk A/S’ diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co.’s Trulicity.

Read More »

Indivior drug to fight opioid addiction approved by U.S. FDA

Indivior’s experimental drug to help fight America’s growing opioid addiction crisis was approved by the U.S. Food and Drug Administration, boosting the company’s sales prospects as competitors threaten revenues from an older product.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom